NCT02231788

The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy

A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial to Evaluate the Efficacy of Telmisartan/S-Amlodipine(Telminuvo® Tab. 40/2.5mg) on 24-hour Ambulatory BP Control Compared With Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 217 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP Control Compared with Telmisartan Monotherapy

Detailed description

A multicenter, Prospective, Randomized, Open-label, Phase 4 Trial designed to Evaluate the Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP Control Compared with Telmisartan Monotherapy

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Telminuvo®Tab. 40/2.5mg	Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
DRUG	Telmitrend®Tab. 80mg	Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg

Timeline

• Start date: 2014-06-01
• Primary completion: 2018-03-01
• Completion: 2018-03-01
• First posted: 2014-09-04
• Last updated: 2020-01-31

Locations

11 sites across 1 country: South Korea